Aileron Therapeutics, Inc. Profile Avatar - Palmy Investing

Aileron Therapeutics, Inc.

Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell…

Biotechnology
US, Boston [HQ]
US · Macroeconomic Factors/Risks · Forecasts

Macro

Aileron Therapeutics, Inc. mainly operates in US (Alpha-2: US, Alpha-3: USA)

United States
Analysis Results
B Overall Rating
19 Analyzed Indicators
B Annual Indicators Rating
16 Analyzed Indicators
B+ Monthly Indicators Rating
3 Analyzed Indicators
Breakdown

All indicators comes from high quality sources, such as the world bank, OECD, FRED and manuel datasets such as Premiums by Prof. Damodaran.

End of ALRN's Analysis
CIK: 1420565 CUSIP: 00887A105 ISIN: US00887A2042 LEI: - UEI: -
Secondary Listings
ALRN has no secondary listings inside our databases.